UCL  IRIS
Institutional Research Information Service
UCL Logo
Please report any queries concerning the funding data grouped in the sections named "Externally Awarded" or "Internally Disbursed" (shown on the profile page) to your Research Finance Administrator. Your can find your Research Finance Administrator at https://www.ucl.ac.uk/finance/research/rs-contacts.php by entering your department
Please report any queries concerning the student data shown on the profile page to:

Email: portico-services@ucl.ac.uk

Help Desk: http://www.ucl.ac.uk/ras/portico/helpdesk
Publication Detail
New therapeutic targets for the antiphospholipid syndrome.
  • Publication Type:
    Journal article
  • Publication Sub Type:
    Journal Article
  • Authors:
    Pericleous C, Ioannou Y
  • Publication date:
    12/2010
  • Pagination:
    1291, 1299
  • Journal:
    Expert Opin Ther Targets
  • Volume:
    14
  • Issue:
    12
  • Status:
    Published
  • Country:
    England
  • Language:
    eng
  • Keywords:
    Abortion, Habitual, Antibodies, Antiphospholipid, Anticoagulants, Antiphospholipid Syndrome, B-Lymphocytes, Blood Platelets, Endothelial Cells, Female, Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Molecular Targeted Therapy, Pregnancy, Pregnancy Complications, Thrombosis
Abstract
IMPORTANCE OF THE FIELD: The antiphospholipid syndrome (APS) is an autoimmune condition whereby pathogenic antiphospholipid antibodies (aPL) cause vascular thrombosis and/or recurrent miscarriage, and carries a high burden of morbidity and mortality. Currently the only proven treatment is long-term anticoagulation, which is not effective in all patients and carries risk of haemorrhage. AREAS COVERED IN THIS REVIEW: Novel therapeutic targets that are currently being explored for APS in order to address the unmet needs of better, safer and ideally targeted therapy. These include B cell depletion, new-generation anticoagulants, interfering with aPL cell-mediated activation of endothelial cells and platelets both at the cell surface level and intracellularly, targeting components of the complement system and the novel concept of using decoy peptides to target only the pathogenic sub-population of aPL. WHAT THE READER WILL GAIN: An overview of the potential targets and rationale underpinning them. TAKE HOME MESSAGE: Though current options remain limited for the treatment of APS, the future holds much promise with the identification of multiple targets, many of which are currently being explored. The challenge will be to undertake carefully designed prospective multi-centre trials to generate the evidence necessary to support integration of such candidates into clinical practice.
Publication data is maintained in RPS. Visit https://rps.ucl.ac.uk
 More search options
UCL Researchers
Author
Div of Medicine
University College London - Gower Street - London - WC1E 6BT Tel:+44 (0)20 7679 2000

© UCL 1999–2011

Search by